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ABSTRACT
Currently several combination treatments of mTor- and Ras-pathway inhibitors 
are being tested in cancer therapy. While multiple feedback loops render these central 
signaling pathways robust, they complicate drug targeting.
Here, we describe a novel H-ras specific feedback, which leads to an inadvertent 
rapalog induced activation of tumorigenicity in Ras transformed cells. We find that 
rapalogs specifically increase nanoscale clustering (nanoclustering) of oncogenic 
H-ras but not K-ras on the plasma membrane. This increases H-ras signaling output, 
promotes mammosphere numbers in a H-ras-dependent manner and tumor growth 
in ovo. Surprisingly, also other FKBP12 binders, but not mTor-inhibitors, robustly 
decrease FKBP12 levels after prolonged (>2 days) exposure. This leads to an 
upregulation of the nanocluster scaffold galectin-1 (Gal-1), which is responsible 
for the rapamycin-induced increase in H-ras nanoclustering and signaling output. 
We provide evidence that Gal-1 promotes stemness features in tumorigenic cells. 
Therefore, it may be necessary to block inadvertent induction of stemness traits in 
H-ras transformed cells by specific Gal-1 inhibitors that abrogate its effect on H-ras 
nanocluster. On a more general level, our findings may add an important mechanistic 
explanation to the pleiotropic physiological effects that are observed with rapalogs.
INTRODUCTION
Cancer stem cells (CSC) are critical for tumor 
seeding and growth [1]. They have been identified in a 
variety of cancers, typically with the help of surface 
markers, such as CD44+/CD24- for breast CSC [2]. 
Moreover, CSC can be enriched by culturing them as 
tumorospheres [3]. Due to the drug resistance of CSC, 
specific drugs are needed that so far did not follow the 
rational of targeted therapy.
Currently combinations of mTOR- and MAPK-
pathway inhibitors are being tested for the treatment of 
cancer [4, 5, 6]. Both pathways operate downstream of 
Ras broadly driving cellular growth and cell division. 
Notably, a net overactivation of these pathways is 
observed in almost all types of cancer [7]. This has led to 
the development of an arsenal of kinase inhibitors against 
mTOR or PI3K, but also MAPK-pathway components 
such as Raf, Mek and Erk [4, 8]. Classically, mTORC1, 
but less mTORC2 was inhibited by rapamycin and 
analogues (called rapalogs). Rapamycin and its analogs 
bind to FK506-binding protein 12 (FKBP12) thus forming 
an inhibitory complex that allosterically blocks the activity 
of mTORC1 [9]. In addition, FKBP12 negatively regulates 
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H-ras signaling. Being a prolylisomerase, it catalyzes 
isomerization of a C-terminal proline of H-ras, which 
facilitates H-ras depalmitoylation and decreases H-ras 
plasma membrane residence [10]. Therefore, FKBP12 
inhibitors can acutely promote H-ras signaling output.
Hotspot mutations in codon 12, 13 and 61 render 
Ras constitutively active and make it a major driver 
in cancer [11]. Unfortunately, we still lack clinically 
approved inhibitors against either of the cancer associated 
Ras isoforms H-ras, N-ras and K-ras with the two 
splice isoforms 4A and 4B [8]. The focus is currently 
on K-ras4B (herafter K-ras) specific inhibitors, as K-ras 
is the most frequently mutated Ras isoform and was 
recently established as a specific driver of stemness in 
cancer cells and target of cancer stem cell drugs [12, 
13]. This contrasted with H-ras, which established itself 
seemingly as a counterbalance of K-ras in cancer and non-
transformed cells [12, 14].
While details for the different oncogenic qualities 
of H-ras and K-ras are still incompletely understood, it is 
well established that functional differences already emerge 
within the plasma membrane. Cancer associated Ras-
isoforms H-ras, N-ras and K-ras are laterally segregated 
into nanoscale domains and display conformational 
differences in the membrane [15, 16]. Importantly, 
nanoscale oligomerisation of Ras into so called nanocluster 
correlates with effector recruitment efficiency and MAPK-
signaling output [17, 18]. Galectin-1 (Gal-1) positively 
regulates GTP-H-ras- and negatively GTP-K-ras- 
nanocluster [19]. Furthermore, Gal-1 has a pro-angiogenic 
and pro-migratory effect in gliomas and melanomas [20]. 
In other cancer types, e.g. breast cancer, Gal-1 knockdown 
improved drug sensitivity [21]. Altogether, increased Gal-
1 levels have been associated with more aggressive tumor 
progression. This led to the development of inhibitors that 
are typically directed against the carbohydrate binding 
activity of the protein [22].
Here, we show that rapalogs degrade their target 
FKBP12, which upregulates the H-ras specific nanocluster 
scaffold Gal-1, MAPK-signaling, stemness properties and 
tumor growth. Our work suggests that rapalog treatment 
should be combined with a new type of Gal-1 inhibitor that 
interferes with its ability to stabilize H-ras nanocluster.
RESULTS
Rapalogs increase H-ras nanoclustering and 
H-ras-dependent MAPK-signaling
We recently found that the commonly used 
protein synthesis inhibitor cycloheximide (CHX), 
was paradoxically able to increase the number of 
mammospheres and tumor growth in a H-ras dependent 
manner [23]. CHX exhibits a typically neglected 
polypharmacology, as it is not only an inhibitor of protein 
synthesis, but also of FKBP12, which in complex with 
rapalogs inhibits mTORC1.
We therefore tested, whether rapalogs could 
phenocopy the observations made with CHX. Given the 
increasing evidence that H-ras- and K-ras-isoforms have 
distinct, if not partly antagonistic functions [12, 14, 24], 
we employed a FRET-assay, which analyses the densely 
packed, active Ras proteins in isoform-specific signaling 
nanocluster in the membrane [25, 26] (Figure 1A, 1B). 
Treatment of HEK293-EBNA (hereafter HEK) cells with 
rapalogs increased specifically H-rasG12V nanoclustering-
FRET to a similar level as the well-established nanocluster 
scaffold Gal-1 [19] (Figure 1C, 1D). While Gal-1 
significantly decreased K-rasG12V nanoclustering-FRET 
without altering K-rasG12V subcellular distribution 
(Figure 1D and Supplementary Figure 1A), treatment with 
rapalogs had little effect on K-rasG12V nanoclustering-
FRET in HEK cells (Figure 1D).
These effects on the nanoscale organization of Ras 
were confirmed by analyzing the point-pattern distribution 
of immuno-gold labeled Ras on plasma membrane rip-
offs from BHK cells. Rapamycin treatment significantly 
increased the L(r)-r value of H-rasG12V (Figure 1E), 
indicating upmodulated nanoclustering, while having no 
effect on K-rasG12V nanoclustering (Figure 1F).
Consistent with a strong activation of Ras signaling 
by augmented nanoclustering, rapamycin increased pErk 
and pAkt levels similar to CHX-treatment. (Supplementary 
Figure 1B).
Activation of Ras−MAPK-signalling is known to 
induce differentiation of rat adrenal pheochromocytoma 
(PC12) cells, which is visible by neurite outgrowth. 
This assay is therefore reporting on MAPK-activity 
[27]. Accordingly, expression of GFP-H-rasG12V or 
K-rasG12V induced differentiation of PC12 cells, as can 
be seen by neurite formation (Figure 1G). Previously, 
others and we have shown that H-rasG12V-driven PC12 
cell differentiation was increased by treatments that 
increased H-ras nanoclustering, such as Gal-1 expression 
[28] or CHX treatment [23]. In line with the H-ras-specific 
effect of rapamycin on nanoclustering upon rapamycin 
treatment (Figure 1C, 1D), only H-rasG12V transfected 
PC12 cells showed an increased differentiation with 
rapamycin as compared to the non-treated control, while 
K-rasG12V transfected PC12 cells did not (Figure 1G).
Finally, in agreement with a previous report, which 
showed that everolimus could increase MAPK-signaling 
in a PI3K-dependent manner [29], both pharmacological 
inhibition of PI3K activity by wortmannin (Supplementary 
Figure 1C), as well as knockdown of p110α abolished the 
rapamycin-induced effect on H-ras nanoclustering-FRET 
(Supplementary Figure 1D, 1E).
Thus rapalogs increase specifically active H-ras-
nanocluster and signaling output in a PI3K-dependent 
manner.
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Figure 1: Rapalogs specifically activate H-ras nanoclustering and can drive PC12 cell differentiation. (A) Schematic 
illustration of the nanoclustering-FRET assay. FRET is increased due to the formation of transiently immobile signaling complexes, which 
lead to nanoscale clustering of Ras in the plasma membrane. (B) Representative FLIM-FRET images of HEK cells expressing mGFP/
mCherry-H-rasG12V or mGFP/mCherry-K-rasG12V FRET pairs. Image color look-up table on the right shows fluorescence lifetimes, 
with low lifetimes indicating high FRET and high lifetimes indicating low FRET. Scale bar in the images represents approximately 20 μm. 
(C and D) Nanoclustering-FRET analysis in HEK cells co-expressing mGFP- and mCherry-tagged (C) H-rasG12V or (D) K-rasG12V. 
Cells were treated for 24 h with DMSO control, 0.5 μM rapamycin or 2 μM everolimus. In addition, co-expression of FRET pairs with 
Galectin-1 was used for comparison. The numbers in the bars indicate the number of analyzed cells (mean ± SEM, n=3). (E and F) Electron 
microscopic nanoclustering analysis of BHK cells expressing mGFP-tagged (E) H-rasG12V, (F) K-rasG12V with or without 0.5 μM of 
rapamycin. Intact apical plasma membrane sheets were immunolabeled with 4.5 nm gold nanoparticles coupled to anti-GFP antibody. The 
spatial distribution of gold particles was evaluated using univariate K-function, where L(r)–r values indicate the extent of nanoclustering 
as a function of the length scale, r, in nm. At least 15 images were analysed for each condition. Statistical significance between different 
conditions was evaluated using bootstrap tests. Averaged curves are shown for each condition. (G) PC12 cells transiently transfected with 
(left) mGFP-H-rasG12V or (right) mGFP-K-rasG12V were incubated with DMSO control or 0.5 μM rapamycin. After 72 h, GFP-positive 
cells were scored for neurites. Results (top) are plotted as percent of cells (mean ± SEM, n = 4) with neurite outgrowth >1.5 times the 
diameter of the cell body. Representative images of cells (bottom) scored for neurites are shown. Bar represents 200 μm.
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Rapalogs promote mammosphere formation 
and in ovo tumor growth in a H-ras-dependent 
manner
As previously observed with CHX [23], rapalogs 
significantly increased MDA-MB-231 mammosphere 
formation in a H-ras dependent manner (Figure 2A, 
2B). Note, that H-ras knockdown alone increased sphere 
formation relative to the scramble control, consistent 
with its negative effect on K-ras nanoscale organization 
and signaling, which is mediated by perturbation of the 
phosphatidylserine distribution by oncogenic H-ras [24]. 
This sharply contrasted with the effect of mTor kinase 
inhibitors, which highly significantly blocked sphere 
formation (Supplementary Figure 2A). In agreement 
with the increased mammosphere numbers, rapamycin 
increased tumor growth when MDA-MB-231 cells were 
xenografted onto the chorioallantoic membrane of chick 
embryos for in ovo tumor formation [30] (Figure 2C).
Interestingly, MDA-MB-231 cells carry a 
K-rasG13D mutation, suggesting that the pro-
tumorigenic effect is communicated by endogenous, 
Figure 2: Rapalogs promote tumorigenicity H-ras dependently. (A and B) Mammosphere formation efficiency of MDA-MB-231 
cells grown in non-adherent conditions. Mammospheres, (A) not transfected or (B) transfected with scrambled or H-ras siRNA, were 
allowed to form for 6 days and treated for additional 3 days with either DMSO control, 0.5 μM rapamycin or 2 μM everolimus (n=3). (C) 
Left, representative images oftumors derived from MDA-MB-231 cells after transplantation onto chick embryo CAM and treated for 4 days 
with either DMSO control or 0.5 μM rapamycin. Right, the tumor weight was calculated from 12 tumors from four independent experiments 
(mean ± SEM). (D to F) Sphere-forming efficiency of (D) HEK transiently expressing mGFP-H-rasG12V or (E) mGFP-K-rasG12V, or (F) 
wildtype HEK cells grown in non-adherent conditions. Spheres were allowed to form for 6 days and treated for additional 3 days with either 
DMSO control, 0.5 μM rapamycin, 2 μM everolimus, 2 μM WYE-125132 or 0.25 μM torin 1 (n=3). (A-F) Statistical comparisons are done 
with the dark-grey highlighted control samples. Notice that in (B) this is the siRNA H-ras treated sample.
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wildtype (wt) H-ras in these cells. However, neither 
rapamycin, nor everolimus did have a positive effect on 
MCF7 sphere numbers, which are wildtype for Ras, but 
decreased mammospheres as TOR-kinase inhibitors did 
(Supplementary Figure 2B). By contrast, everolimus 
significantly increased sphere numbers in H-rasG12D-
mutated Hs578T (Supplementary Figure 2C).
In order to understand, whether the observed 
sphere growth modulation depends on the expression 
of oncogenic Ras, we employed spheres derived from 
RasG12V-expressing HEK cells [31]. This model 
reproduced the significantly higher potential of oncogenic 
K-ras to increase sphere numbers, as compared to 
oncogenic H-ras (Supplementary Figure 2D, 2E) [12].
Intriguingly, HEK cells that were transfected either 
with H-rasG12V or K-rasG12V recapitulated the rapalog-
induced increase in sphere numbers that was observed 
in breast cancer cell lines, while remaining sensitive to 
mTOR inhibitors (Figure 2D, 2E). By contrast, wt HEK 
cell derived spheres were sensitive to all of these inhibitors 
(Figure 2F), as observed for MCF7 cells (Supplementary 
Figure 2B).
Therefore rapalogs have the potential to increase the 
sphere-forming capacity of tumorigenic cells that were 
reprogrammed with oncogenic Ras.
Reciprocal regulation of FKBP12 and galectin-1 
links FKBP12-level modulation to H-ras 
nanoclustering
We next asked, whether downmodulation of 
FKBP12 levels could phenocopy the nanoclustering 
effects of rapalogs. Indeed, this was seen after 
knockdown of FKBP12, which specifically increased 
H-ras nanoclustering-FRET (Figure 3A), but had only a 
very small effect on K-ras nanoclustering-FRET (Figure 
3B). Conversely, increased expression of FKBP12 
downmodulated specifically H-rasG12V nanoclustering-
FRET (Figure 3A) [10], but had no effect on K-ras 
nanoclustering-FRET (Figure 3B).
So far, we only know of the nanocluster scaffold 
Gal-1 as a positive modulator specifically of H-ras 
nanoclustering. Consistent with an involvement of Gal-
1, knockdown of Gal-1 significantly attenuated the 
positive effect of rapamycin on H-ras nanoclustering 
(Supplementary Figure 3A). We therefore examined the 
expression of Gal-1 upon FKBP12-level modulation in 
wt HEK or HEK expressing oncogenic Ras. Intriguingly, 
knockdown of FKBP12 significantly upregulated Gal-
1 levels, while FKBP12 overexpression had no or just 
a small effect on Gal-1 expression (Figure 3C, 3D and 
Supplementary Figure 3B, 3C).
Conversely, we found that the knockdown of Gal-1 
strongly downmodulated FKBP12 levels, while high Gal-1 
overexpression increased FKBP12 levels in wt and Ras-
expressing HEK cells (Figure 3C, 3D and Supplementary 
Figure 3B, 3C). Thus each of these four expression 
manipulations resulted in a specific set of Gal-1- and 
FKBP12-level combinations (Table 1).
In agreement with the nanoclustering changes 
(Figure 1C, 3A), Gal-1 overexpression and FKBP12 
knockdown led to a similar increase in pErk and pS6K1 
levels in H-rasG12V transfected HEK cells (Figure 3E). 
However, as observed by others and us [25, 32], high 
levels of Gal-1 decreased pAkt, while FKBP12 knockdown 
increased it (Figure 3E). No significant changes of the 
above phosphoproteins were observed when Gal-1 was 
knocked down or FKBP12 was overexpressed (Figure 3E).
In line with the negative effect of Gal-1 on 
K-rasG12V-nanoclustering, pErk levels were significantly 
decreased, while pS6K1 was somewhat increased and 
pAkt remained unchanged in Gal-1 overexpressing 
K-rasG12V-HEK cells (Figure 3F). By contrast, 
phosphorylation of pErk remained unchanged, while pAkt 
and pS6K1 were significantly increased in those cells after 
FKBP12 knockdown (Table 1).
These data imply that downmodulation of FKBP12 
increases H-ras nanoclustering by the associated Gal-1 
upregulation.
Galectin-1 and FKBP12 level modulation affect 
mammosphere formation
Given the similarities of the rapalog- and FKBP12-
induced nanoclustering responses, we hypothesized that 
loss of FKBP12 may increase mammospheres. Indeed, 
knockdown of FKBP12 increased sphere formation 
in H-rasG12D mutated Hs578T (Figure 4A, 4D). 
Interestingly, the same was not only observed with Ras 
wt MCF7 spheres (Figure 4B, 4D), but also in K-rasG13D 
mutant MDA-MB-231 spheres (Figure 4C, 4D). By 
contrast, overexpression of FKBP12 basically abrogated 
mammosphere formation from all of these three cell 
lines (Figure 4A-4D). Hence, FKBP12 upregulation may 
have effects that do not correlate with the Erk- and Akt-
signaling (Figure 3E, 3F), but with its effect on H-ras 
nanoclustering-FRET (Figure 3A) [10].
Low FKBP12 levels also lead to high Gal-1 levels 
(Supplementary Figure 3C), suggesting that Gal-1 could 
be responsible for the increased sphere growth with 
decreased FKBP12 levels. Indeed, Gal-1 overexpression 
phenocopied the sphere promoting effect of the FKBP12 
knockdown in Hs578T and MCF7 cells (Figure 4A, 4B, 
4D), but not in MDA-MB-231 cells (Figure 4C, 4D). In 
fact, the decreased sphere growth in K-ras-mutant MDA-
MB-231 cells was consistent with the negative effect of 
Gal-1 on active K-ras nanoclustering (Figure 1B, 1D).
In order to understand how much the observed 
sphere growth modulation depends on the Ras-mutation 
status as compared to other mutations, we employed 
again the HEK-cell derived sphere model. Comparison 
of Figure 4A-4D with Figure 4E-4H clearly demonstrates 
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that the HEK-spheres phenocopied the treatment response 
of the breast cancer cell lines, if both expressed the same 
oncogenic Ras-isoform (Figure 4A, 4E and 4C, 4G). These 
data suggest that Gal-1 promotes sphere growth in Ras wt 
and oncogenic H-ras transformed cells.
Gene expression analysis suggests a galectin-1-
associated stemness program
In order to understand what genetic characteristics 
are responsible for the sphere growth promotion by Gal-1 
overexpression or FKBP12 knockdown, we analyzed the 
expression of genes that we previously associated with a 
K-ras directed CSC-drug response in HEK cells with the 
respective manipulations [13].
This analysis revealed a similar overall gene 
expression response of HEK cells with overexpressed Gal-
1 or downmodulated FBKP12 (Figure 5A). Intriguingly, 
the Gal-1 gene (LGALS1) was also significantly increased 
in HEK cells cultured as spheres (3D), as compared to 
those grown on plastic (2D) (Figure 5B).
Consistently, we could show that Gal-1 
overexpression and FKBP12 knockdown in HEK cells 
upregulated the stemness marker CD44, thus establishing 
Figure 3: A galectin-1-dependent FKBP12 rescue-loop is activated upon rapalog-induced FKBP12 downmodulation. 
(A and B) Nanoclustering-FRET analysis in FKBP12 knockdown/overexpressing HEK cells co-expressing mGFP- and mCherry-tagged 
(A) H-rasG12V or (B) K-rasG12V. The numbers in the bars indicate the number of analyzed cells (mean ± SEM, n=4). (C and D) Western 
blot analysis in HEK cells transfected with the indicated FKBP12 or Gal-1 siRNAs, and in addition expressing (C) mGFP-H-rasG12V or 
(D) mGFP-K-rasG12V. Control is transfected with empty vector, while pcDNA marks exogenous expression of protein indicated on top 
of the blots. Numbers indicate β-actin normalized protein levels (n=4). (E and F) Western blot analysis of Ras and mTORC1 signaling in 
HEK cells expressing (E) mGFP-H-rasG12V or (F) mGFP-K-rasG12V under indicated FKBP12 or Gal-1 manipulations as in (C and D). 
Numbers indicate the ratio of phosphorylated to respective total protein levels (n=3).
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Table 1: Summary of major experimental results
 
 
  H-rasG12V K-rasG12V  
sphere
formationGal-1 FKBP12
nano-
clustering pERK pAKT pS6K
nano-
clustering pERK pAKT pS6K
Gal-1 + + + + – + – – 0 + + *
siFKBP12 + – + + + + – 0 + + +
siGal-1 – – 0 0 0 0 n.d. 0 0 0 –
FKBP12 0 # + – 0 0 0 0 0 0 0 –
Changes relative to control conditions are denoted with + for increased and – for decreased parameters; 0 means 
no significant change and n.d. not determined. Left column shows manipulations: overexpression of Gal-1 (Gal-
1), knockdown of FKBP12 (siFKBP12), knockdown of Gal-1 (siGal-1) and overexpression of FKBP12 (FKBP12). 
Sphere formation was analyzed in Hs578T, MCF7, MDA-MB-231 and HEK cells with and without oncogenic 
H-ras or K-ras expression. The symbol # indicates that a decrease in Gal-1 expression was observed only in oncogenic 
K-ras expressing cells. The symbol * indicates that sphere growth was not observed in oncogenic K-ras expressing 
cells.
Figure 4: Galectin-1- and FKBP12-level modulation affects sphere formation consistent with their effects on Ras 
nanoclustering. (A to C) Effect of Gal-1 and FKBP12 level modulation on Hs578T (A), MCF7 (B) and MDA-MB-231 (C) cell sphere 
formation. Cells were transfected with the indicated expression constructs or siRNA (si pre-fix), and spheres were allowed to form for 9 
days (n=4). (D) Representative images of cancer cell spheres from (A-C). Bar in the images represents 1000 μm. (E to G) Effect of Gal-1 
and FKBP12 level modulation on sphere formation of wildtype or (E), H-rasG12V- (F) or K-rasG12V- (G) expressing HEK cells. Cells 
were transfected with the indicated expression constructs or siRNA (si pre-fix), and spheres were allowed to form for 9 days (n=3). (H) 
Representative images of HEK spheres from (E-G). Bar in the images represents 1000 μm.
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a CD44+/CD24- population which is also known to 
form aggressive tumors (Figure 5C) [31]. Also another 
gene, PTRF, that we previously associated with a more 
fibroblast-like [13], as compared to embryonic stem cell 
(ESC)-like gene signature was significantly increased in 
3D-HEK (Figure 5B). However, none of this was observed 
for K-ras mutated MDA-MB-231 cells grown in 3D vs. 
2D (Figure 5A, 5B).
We therefore tentatively conclude that Gal-1 is 
associated with a different, possibly opposite H-ras-
driven stemness program (fibroblast-like), than the K-ras 
associated ESC-like program that we have previously 
described [13].
Rapalogs induce downmodulation of FKBP12 
thus increasing galectin-1 expression
The above results suggest that upregulation of 
Gal-1 after loss of FKBP12 promotes stemness in a 
H-ras dependent manner. We therefore scrutinized, the 
connection of the rapalog and FKBP12 knockdown 
effect.
Figure 5: Gene expression analysis with RNA-seq supports stemness promoting activity of galectin-1. (A) Hierarchical 
clustering of samples using genome-wide RNA-seq data. Replicate samples (n=3) in each group are averaged and Euclidean distance is 
used as distance metric. (B) Heatmap of fold-changes (log2 scale) comparing each treatment group vs. 2D cultured control group for the 
genes of the K-ras nanoclustering associated gene signature. Right table shows the two-types of identified gene regulations of which the 
ESC-like type was predictive for K-ras directed CSC-drug response (10). * FDR < 0.05; ** FDR < 0.01; *** FDR < 0.001. (C) Left, CD44/
CD24 FACS profiles are shown for HEK after FKBP12 or Gal-1 manipulation. Right, shown is the average percentage of CD44+/CD24− 
HEK cells. Error bars denote the SEM from three independent experiments performed in duplicate.
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Intriguingly, a loss of FKBP12 expression was 
observed in several cell lines with all FKBP12 binders, 
such as FK506 and a derivative of CHX, DM-CHX, 
which does not block protein synthesis [33], as well as 
with rapalogs (Figure 6A-6E). By contrast, mTor-kinase 
inhibitors torin 1 or WYE-125132 did not change FKBP12 
levels (Figure 6A-6E).
A detailed analysis of the protein level changes after 
Gal-1- and FKBP12-level manipulations (Supplementary 
Figure 3C) revealed a Ras-isoform modulated Gal-1 
mediated ‘rescue loop’ of FKBP12 expression. Thus 
FKBP12 levels are Gal-1 dependently reinduced, if 
they fall low (Figure 7A). Notably, the level of FKBP12 
induction by Gal-1 was significantly lower in HEK cells 
overexpressing H-rasG12V or K-rasG12V, while the 
induction of Gal-1 by the knockdown of FKBP12 was 
somewhat increased by H-rasG12V but not K-rasG12V 
(Supplementary Figure 3C). This indicates that in the 
presence of oncogenic Ras, FKBP12 expression is 
relatively less induced, if Gal-1 levels are high (Figure 
7A, [2]). More importantly, Gal-1 levels seem to be 
relatively higher induced with low FKBP12 levels only in 
H-rasG12V expressing cells (Figure 7A, [1]). Therefore, 
in particular with oncogenic H-ras, higher Gal-1 levels and 
lower FKBP12 levels are promoted, overall supporting the 
H-ras stemness state.
This reciprocal regulation of FKBP12 and Gal-1 had 
interesting consequences, if tumorigenic cells were treated 
with rapamycin over the course of several days. Within 
two days after rapamycin treatment of HEK cells, FKBP12 
levels decreased, while Gal-1 levels concomitantly 
increased (Figure 7B). Importantly, after FKBP12 is lost 
on day 2, high Gal-1 levels were followed by FKBP12 
reexpression (Figure 7B).
Importantly, very similar observations were made 
when HEK cells were grown as spheres (Supplementary 
Figure 4A), supporting the significance of this reciprocal 
regulation also in sphere cultures. Basically the same 
Figure 6: FKBP12-binding compounds stimulate FKBP12 downmodulation and couple Gal-1 induction. (A to E) Western 
blot analysis of Gal-1 and FKBP12 protein levels in (A, D) HEK, (B, E) MDA-MB-231 and (C) Hs578T cells upon FKBP12 knockdown 
or treatment with 0.5 μM rapamycin, 2 μM everolimus, 0.25 μM torin 1, 0.18 μM CHX, 10 μM DM-CHX, 0.5 μM FK506 or 2 μM WYE 
-125132. Cells were treated for 48 h. Numbers indicate β-actin normalized protein levels (n=3).
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occurred in MDA-MB-231 and Hs578T cells (Figure 7C, 
7D), where however FKBP12 levels (and Gal-1 levels) are 
higher than in HEK cells to begin with (Supplementary 
Figure 4B). As a consequence FKBP12 expression is lost 
only on day 4. This rapamycin treatment induced FKBP12 
degradation has therefore important consequences, 
as it promotes sphere growth, as long as Gal-1 levels 
are elevated (Figure 7A, [1]) and mTORC1 activity is 
not blocked (Figure 7B, day 6). Due to the reciprocal 
regulation of FKBP12 and Gal-1, and depending on the 
actual levels of these proteins, transient periods of sphere 
growth promotion may occur in a cyclic manner.
DISCUSSION
The nested mTOR- and Ras-pathways are of 
critical importance to maintain tumor growth. Failure of 
mTORC1 inhibitors to efficiently kill cancer cells and the 
existence of multiple feedback loops require combinations 
with inhibitors, such as against the Ras/MAPK-pathway 
[5]. However, given that K-ras and H-ras appear to 
have different roles to promote stemness also in cancer 
cells [12, 14], it is critical to understand what the exact 
contributions from these individual Ras isoforms are in 
cancer.
Figure 7: Rapamycin induces downmodulation of FKBP12 thus increasing galectin-1 expression. (A) Proposed regulation 
scheme for Gal-1-dependent FKBP12-rescue loop. Low and High denotes concentration of proteins in the cell. Boxed numbers refer to 
stages in (B, C and D). Small arrows and block lines indicate modulators. (B to D) Western blot analysis of Gal-1 and FKBP12 protein levels 
in (B) HEK, (C) MDA-MB-231 and (D) Hs578T cells upon FKBP12 knockdown or rapamycin treatment for 6 days. Numbers indicate 
β-actin normalized protein levels. pS6K1 is shown as a marker of mTorC1 activity, and numbers indicate the ratio of phosphorylated to 
respective total protein levels (n=3). Arrows on top indicate when rapamycin treatment was refreshed. Boxed numbers on bottom relate to 
the steps in (A).
Oncotarget44560www.impactjournals.com/oncotarget
We found that prolonged exposure of tumorigenic 
cells with rapalogs decreases FKBP12 levels (Figure 6), 
which potentially leads to hyperactivation of the mTORC1-
pathway (Figure 3E, 3F). We are intrigued by the finding 
that a number FKBP12 binders degrade their target in 
several cell lines (Figure 6). Considering that rapamycin 
has been studied for many years, it is surprising that this 
has not been described before. It remains to be shown, 
whether this also applies to other FKBPs, such as FKBP51 
and FKBP52 [34] and what the specific consequences 
would be. Most importantly however, loss of FKBP12 
induces high Gal-1 levels, which increase specifically 
H-ras nanoclustering and thus MAPK-signaling output. 
Our data suggest that this could at least transiently increase 
tumor growth after rapalog exposure (Figure 8).
Similar to the FKBP12-associated mechanism 
described by Mark Philips group, our mechanism would 
promote H-ras signaling output. However, in Ahearn et al. 
acute inhibition of FKBP12 increases plasma membrane 
residence of H-ras [10]. By contrast, we observed FKBP12 
degradation induced upregulation of Gal-1, which creates 
a delay of 2-4 days, while also lasting for 1-2 days. We 
consider the longer time frame of activity more relevant 
for cellular differentiation changes and establishment 
of stemness features. In support of this, it was recently 
observed that rapamycin induces the transcription of 
stemness factors such as Oct4, Sox2 and Nanog, while 
preventing replicative senescence in fibroblasts [35].
Comparison of sphere-formation data after rapalog 
treatment and knockdown of FKBP12 suggest that 
increased sphere growth after rapalog treatment requires 
expression of oncogenic Ras to sustain higher mTorC1 
activity and probably also to support the induction 
of higher Gal-1 levels. Moreover, Gal-1 knockdown 
data from oncogenic K-ras expressing cells show that 
the loss of Gal-1 that is leading to a loss of FKBP12, 
is not promoting sphere growth as the loss of FKBP12 
alone (which also increases Gal-1). This suggests that 
increased Gal-1 levels promote sphere growth of K-ras 
transformed cells only in the absence of FKBP12. These 
results also explain, how Gal-1 can execute paradoxical, 
opposite actions in cancer cells, which would depend 
on the expressed oncogenic Ras isoform and FKBP12 
levels. However, most significantly in terms of new 
CSC-drug target identification, knockdown of Gal-1 
or overexpression of FKBP12 always reduced sphere 
formation, irrespective of which oncogenic Ras was 
expressed (Figure 4A-4H).
We propose that interference with the H-ras 
nanocluster-promoting activity of Gal-1 may present an 
important target in this context. This may require novel 
inhibitors against Gal-1 that interfere with its activity to 
complex in particular with the Raf effectors; an interaction 
which is required for its nanocluster promoting activity 
[19]. Interestingly, the Gal-1 inhibitor OTX008, which is 
not a classical carbohydrate binding region competitor, 
Figure 8: Summary scheme illustrating how rapalogs affect stemness and tumorigenicity. Prolonged rapalog treatment 
decreases FKBP12 levels (dotted lines), which leads to an increase of Gal-1 expression and de-repression of mTORC1 signaling. Gal-1 
stabilizes nanocluster of active H-ras, thus promoting MAPK-signaling. In addition Gal-1 stimulates other stemness features, such as 
CD44-expression. Altogether, these changes may increase tumorigenicity in certain situations.
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was recently shown to synergize with rapamycin to block 
tumor growth [36]. Intriguingly, an OTX008 related 
compound binds at a Gal-1 site that may allosterically 
affect its binding to Raf-effectors or Gal-1 dimerization 
and hence its nanocluster scaffolding activity [37]. More 
generally, our work suggests that rapalog treatment should 
be combined specifically with H-ras signaling inhibition 
to prevent possibly detrimental shifts in MAPK- and Akt-
signaling with consequences for stemness induction.
Given the transient nature of the rapalog induced 
FKBP12 degradation (due to the rescue-loop) and the 
dependence of the effect on cellular FKBP12 levels, 
as well as on the efficacy of FKBP12 degradation, it is 
obvious that current use of rapalogs does not massively 
lead to problems in the clinic. It therefore remains to 
be seen, whether rapalogs more frequently increase the 
cancer cell stemness-associated metastatic risk, as recently 
observed for everolimus [38].
MATERIALS AND METHODS
Materials
Reagents were obtained from the following sources. 
Antibodies to phospho-T202/Y204 Erk (catalogue no. 
9101), Erk (no. 9102), Akt (no. 9272), phospho-T389 
S6K1 (no. 9234), S6K1 (no. 9202), phospho-S235/S236 S6 
(no. 2211), S6 (no. 2217) and PI3K p110α (no. 4255) were 
from Cell Signaling Technologies (Danvers, MA, USA); 
phospho-T308 Akt (no. MAB7419) from R&D Systems 
(Wiesbaden, Germany); FKBP12 (no. 610808) from BD 
Biosciences (San José, CA, USA); galectin-1 (no. 500-
P210) from Peprotech (Hamburg, Germany); the secondary 
anti-mouse (no. sc-2954) and anti-rabbit (no. sc-2004) 
antibodies were from Santa Cruz (Paso Robles, CA, USA); 
GFP (no. 3999-100) was from Bio-Vision (Milpitas, CA, 
USA) and β-actin (no. A1978) from Sigma (Sigma-Aldrich, 
Helsinki, Finland). The compounds everolimus and WYE-
125132 were from SelleckChem (Rungsted, Denmark), 
rapamycin was from Thermo Fisher Scientific (Grand 
Island, NY, USA), torin 1 was from Tocris Bioscience 
(Bristol, UK), cycloheximide was from Acros Organics 
(Thermo Fisher Scientific), wortmannin was from Cell 
Signaling Technologies, FK506 and compactin were from 
Sigma. 50x B27 supplement, horse serum, Opti-MEM and 
transfection reagents Lipofectamine 3000 and RNAiMAX 
were from Thermo Fisher Scientific; Transfection reagent 
JetPrime was from Polyplus (Illkrich-Graffenstaden, 
France); Dulbecco’s Modified Eagle Medium (DMEM), 
Roswell Park Memorial Institute (RPMI), EGF and FGF 
were from Sigma.
Cell culture
Human Embryonic Kidney 293-EBNA (HEK), 
BHK21, MCF7 and Hs578T cells were cultured in DMEM 
(Sigma-Aldrich, Helsinki, Finland). MDA-MB-231 cells 
were cultured in RPMI. Media were supplemented with 
10% fetal bovine serum and 1% L-glutamine. Rat adrenal 
pheochromocytoma (PC12) cells were cultured on plates 
coated with 50 μg/mL of rat tail collagen I (Gibco) in 
Roswell Park Memorial Institute (RPMI)-1640 medium 
(Invitrogen) supplemented with 10% horse serum, 5% 
FBS, 1% L-glutamine, 100 U/mL penicillin, and 100 μg/
mL streptomycin. All cells were incubated at 37°C with 
5% CO2. They were grown typically to a confluency of 
80% and subcultured every 2–3 days. Transfections 
were performed with JetPRIME (Polyplus, Illkrich-
Graffenstaden, France) unless otherwise stated.
DNA constructs and siRNA
Plasmids pmGFP-H-rasG12V, pmGFP-K-rasG12V, 
pcDNA3-Gal-1 were described before [15, 39, 40]. 
PmCherry-RasG12V constructs were generated by 
replacing mGFP from pmGFP-RasG12V with mCherry 
from pmCherry-C1 vector (Clontech Laboratories 
Inc., Mountain View, CA, USA) using NheI and 
BsrGI restriction sites [13]. FKBP12 was amplified 
from pOPINE-eGFP-FKBP12 using the following 
couple of primers: forward 5´-GACCAAGCTTACC 
ATGTCTAGAGGAGTG-3´ and reverse 
5´-GCCAGAATTCTTAATAACT AGTTTCCAG-3´. The 
PCR product was purified and cloned into pcDNA3.1 
vector using HindIII and EcoRI restriction sites. Final 
construct was verified by DNA sequencing (GATC, Köln, 
Germany).
The human gene directed siRNA catalogue numbers 
are as follows: scrambled siRNA (D-001810-10-20), 
siRNA directed against FKBP12 (L-009494-00) and PI3K 
p110α (L-003018-00) were from Dharmacon; siRNA 
directed against Galectin-1 (GS3956) was from Qiagen. 
SiRNA directed against H-ras was a kind gift of Dr. Jukka 
Westermarck [41]. For siRNA transfection JetPrime 
reagent was used, unless otherwise specified.
FRET sample preparation
Compound treatments
HEK cells were seeded on a 6-well plate with glass 
coverslips, and transfected with the donor alone (mGFP-
tagged Ras constructs) in control samples, or together 
with the acceptor using JetPRIME according to the 
manufacturer´s instructions. Acceptors were mCherry-
tagged Ras constructs (mGFP-: mCherry-plasmids at 1:3 
ratio, 2 μg total plasmid). Cells were treated 24 h after 
transfection with either control (DMSO 0.1% (v/v)), 0.5 
μM rapamycin, 2 μM everolimus or 50 nM wortmannin. 
The final DMSO concentration was kept under 0.1%. The 
cells were fixed 24 h after treatments with 4% PFA/PBS 
for 15 min and then washed in PBS, and coverslips were 
mounted with Mowiol 4-88 (Sigma-Aldrich).
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Protein overexpression/knockdown
For analysis of the effect of protein overexpression, 
the cells were cotransfected with mGFP:mCherry plasmid 
Ras FRET pairs (DNA ratio 1:3) together with either 1.5 
μg empty vector (control) or plasmids encoding Gal-1 or 
FKBP12 using JetPRIME reagent. For protein knockdown 
effect analysis, mGFP/mCherry plasmid FRET pairs 
(DNA ratio 1:3) were cotransfected with either scrambled 
siRNA (control), siRNA directed against FKBP12 (20 nM) 
or Gal-1 (50 nM) with JetPRIME reagent and fixation was 
performed 48 hours afterwards. SiRNA directed against 
PIK3CA (25 nM) were transfected with RNAiMAX 
(Thermo-Fischer Scientific, Grand Island, NY, USA) 
according to the manufacturer´s instructions. After 24 h of 
transfection, cells were transfected with mGFP/mCherry 
pairs, and after 48 hours cells were fixed with PFA and 
coverslips were mounted.
FRET-imaging using fluorescence lifetime 
microscopy (FLIM)
The mGFP fluorescence lifetime was measured 
using a fluorescence lifetime imaging attachment 
(Lambert Instruments, Groningen, Netherlands) on an 
inverted microscope (Zeiss AXIO Ovserver.D1, Jena, 
Germany) [18]. For the sample excitation sinusoidally 
modulated 3 W, 497 nm LED at 40 MHz under epi-
illumination was used. Cells were imaged using the 63x, 
NA 1.4 oil objective with the GFP filter set (excitation: 
BP 470/40, beam splitter: FT 495, emission: BP 525/50). 
The phase and modulation were determined using the 
manufacturer’s software from images acquired at 12 phase 
settings. Fluorescein at 0.01 mM, pH 9.0 was used as a 
lifetime reference standard. For each treatment condition, 
the fluorescence lifetime was measured typically for >30 
cells from three biological repeats. The percentage of the 
apparent FRET efficiency (Eapp) was calculated using the 
measured lifetimes of each donor-acceptor pair (τDA) and 
the average lifetime of the donor only (τD) samples. The 
formula employed was Eapp= (1-τDA/τD) x 100%.
Confocal imaging
Confocal samples were prepared on glass bottom 
10 mm microwell dishes (MatTek corporation, Ashland, 
MA, USA). Confocal images from live HEK cells were 
taken with a spinning disk confocal microscope (Marianas 
spinning disk imaging system with a Yokogawa CSU-W1 
scanning unit on an inverted Carl Zeiss Axio Observer Z1 
microscope, Intelligent Imaging Innovations, Inc., Denver, 
USA) using a 63x (NA 1.4 Oil, Plan-Apochromat, M27 
with a DIC III Prism) objective. Images were treated using 
ImageJ 1.49n (National Institutes of Health, Bethesda, 
MD, USA) to adjust for contrast and to display them on 
gray-scale.
Immuno-electron microscopic analysis of Ras 
nanoclustering
The detailed methodology of electron microscopic 
(EM) spatial mapping using the univariate K-function 
analysis can be found elsewhere [42, 43]. Briefly, the 
intact apical plasma membrane sheets of BHK cells 
expressing GFP-tagged constitutively active oncogenic 
Ras isoforms were attached to copper EM grids, which 
were fixed using 4% paraformaldehyde (PFA) and 0.1% 
glutaraldehyde. BHK apical plasma membrane sheets 
were immuno-labeled with 4.5 nm gold nanoparticles 
coupled to anti-GFP antibody, then embedded in uranyl 
acetate and imaged using TEM at 100,000X magnification. 
Gold particle x/y coordinates within a 1-μm2 area on intact 
and featureless plasma membrane sheets were assigned 
using ImageJ. Ripley’s univariate K-function was used to 
quantify the lateral spatial distribution of gold particles 
(Eqs. A and B):
K r n w x x rij i ji j( ) = − ≤
−
≠∑A 2 1( )   (Eq. A)
L r r
K r
r( ) − = ( ) −
pi  
(Eq. B)
where K(r) is the single population K-function for a lateral 
distribution of n points within the total plasma membrane 
area A; r indicates length scale with a range of 1 < r < 240 
nm with 1 nm increments; ||.|| is Euclidean distance. The 
indicator function of 1(.) = 1 if ||xi-xj|| ≤ r and 1(.) = 0 if ||xi-
xj||> r; and wij-1 is the circumferential fraction of the circle 
that has a center located at xi and radius ||xi-xj|| To account 
for points at the edge of the study area, an unbiased edge 
correction was incorporated into the calculation. K(r) 
was then normalized to yield L(r) - r via using a 99% 
confidence interval (99% C.I.) estimated by Monte Carlo 
simulations. For each condition, at least 15 apical plasma 
membrane sheets were imaged, quantified and averaged 
to generate the shown K-function curves. A collection of 
1000 bootstrap samples were constructed to evaluate the 
statistical significance between different conditions [44].
PC12 cell differentiation
PC12 cells were plated in a 8-well Lab-Tek 
chambered coverglass (Nunc Thermo Fischer Scientific) 
coated with 0.1% rat tail collagen I in 30% ethanol. After 
24 h, cells were transfected with GFP-H-rasG12V or 
GFP-K-rasG12V using Lipofectamine 3000 (Thermo- 
Fischer Scientific). Forty-eight hours after transfection, 
cells were treated for 3 days with either DMSO (control) 
or 0.5 μM rapamycin. GFP-expressing cells were imaged 
using an EVOS FL imaging system, and cells were scored 
for extension of neurites longer than 1.5 times the size of 
the cell soma. For each experimental condition, at least 
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100 GFP positive cells from four independent biological 
repeats were analyzed.
In ovo tumor growth assay
Fertilized chicken eggs were placed in an egg 
incubator under rotation in 37°C and 60% humidity on 
day 1 of embryonic development. On day 3 the eggs were 
turned, taken off rotation and punctured with a small hole, 
then covered with adhesive tape. On day 8 the holes were 
expanded and a small plastic ring (5-6 mm in diameter) 
was placed on top of the chorioallantoic membrane 
(CAM). Subsequently, 2 x106 MDA-MB-231 cells were 
suspended in a 1:1 mixture of PBS and matrigel for a total 
volume of 30 μl/egg and transplanted inside the plastic 
ring on the CAM, where after the eggs were sealed with 
parafilm. Tumors were treated daily either with control 
(DMSO 0.05% (v/v) in PBS) or 0.5 μM rapamycin in PBS. 
On day 12 the tumors were excised and fixed in 3% PFA 
overnight in + 4°C (or 1 hour at room temperature), after 
which the tumors were dehydrated with ethanol series of 
50%, 70%, 70% for 1 h each at room temperature and 
finally 70% in + 4°C overnight. The tumors were weighed 
in 70% ethanol using an analytical laboratory scale.
Sphere formation assay
Sphere formation assays were performed using HEK 
wildtype or transiently expressing mGFP-H-rasG12V 
or mGFP-K-rasG12V, MDA-MB-231 (K-rasG13D), 
Hs578T (H-rasG12D), and MCF7 (Ras wildtype) cells. 
For protein expression and knockdown experiments, cells 
were first seeded in 6-well plates and transfected with 
the indicated plasmids or siRNA with JetPRIME reagent 
for HEK and MCF7 cells, or with Lipofectamine 3000 
reagent (Thermo Fisher Scientific) for MDA-MB-231 and 
Hs578T cells. 24 h later they were transferred to 48-well 
suspension culture plates (Cellstar®, Greiner Bio-One, 
Frickenhausen, Germany) at an initial density of 4,000 
cells per well in serum-free media supplemented with 1x 
B27, 25 ng/ml EGF and 25 ng/ml FGF and grown for 9 
days. For compound treatment experiments, 4,000 cells 
per well were plated in 48-well suspension culture plates. 
After 6 days in culture, cells were treated for 3 additional 
days with either control (DMSO 0.1% (v/v)), 0.5 μM 
rapamycin, 2 μM everolimus, 2 μM WYE-125132 or 
0.25 μM torin 1. The spheres were analyzed in an Evos 
FL microscope (Thermo Fisher Scientific) and spheres 
with a size of at least 50 μm were counted. The sphere 
formation under different treatments was expressed as 
percentage normalized to the vehicle treated control. In the 
case of protein overexpression or knockdown samples, the 
samples were normalized to the empty vector or scrambled 
siRNA-transfected controls, respectively, and statistically 
compared.
Immunoblotting
For SDS-PAGE analysis, cells were harvested 
in a buffer containing 50 mM dithiothreitol, 2% 
sodium dodecyl sulfate, 10% glycerol, 150 mM NaCl, 
2 mM EDTA, 0.1 mM EGTA, 50 μg/ml PMSF, 0.1% 
bromophenol blue and 50 mM Tris-HCl, pH 6.8. Proteins 
were first separated using SDS polyacrylamide gels (10-
12%) and then electroblotted on nitrocellulose membranes 
(Perkin Elmer, Waltham, MA, USA). Membranes were 
subjected to immunoblotting with the given antibodies 
and protein bands were detected with enhanced 
chemiluminescence (Clarity Western ECL Substrate, 
Bio-Rad, Helsinki, Finland) on a ChemiDoc MP system 
(Bio-Rad, Hercules, CA, USA). The protein bands were 
analysed with Image-Lab software (Bio-Rad).
RNA-seq profiling
Briefly, 2D-cultured HEK cells untransfected 
(control) or transfected with FKBP12 siRNA or with 
a plasmid encoding rat Gal-1 or treated with 10 μM 
rapamycin for 6 h, 3D-cultured HEK cells and 2D- and 
3D-cultured MDA-MB-231 cells were lysed and total 
RNA was extracted using the RNeasy Mini Kit (Qiagen). 
Quality of RNA samples was evaluated by the RNA 
Integrity Number (RIN) method. The samples were 
next prepared for the sequencing using Illumina TruSeq 
Stranded mRNA Sample Preparation Kit and they were 
sequenced with the HiSeq 3000 instrument using single-
end sequencing chemistry and 50bp read length.
The gene-wise read count values from RNA-
seq data were normalised using TMM normalisation 
as implemented in the edgeR R-package [45]. Prior to 
statistical testing, the data were further transformed 
using the voom approach in the limma R-package [46]. 
Differential expression analysis was then performed 
using the limma R-package, in which the moderate 
t-test was applied according to the specified contrasts 
(comparisons) between different sample groups. The 
statistical significance levels (p-values) were corrected 
for multiple hypotheses testing using false-discovery 
rate (FDR) approach as implemented in the limma R- 
package.
Flow cytometric analysis of CD44+/CD24− cells
HEK cells were grown as spheres for 9 days under 
Gal-1 or FKBP12 level manipulation. Spheres were 
stained with APC-conjugated anti-CD44 (clone G44-26, 
BD Biosciences) antibody and PE-conjugated anti-CD24 
antibody (clone ML5, BD Biosciences) following the 
manufacturer’s instructions. Briefly, spheres were washed 
with phosphate-buffered saline and incubated in 0.05% 
trypsin/0.025% EDTA. Cells were next washed with 
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phosphate-buffered saline containing 2% fetal calf serum 
and 0.1% sodium azide (FACS buffer 1) and resuspended 
in the FACS buffer 1 at 106 cells/100 μl. Fluorochrome-
conjugated monoclonal antibodies were added to the 
cell suspensions at concentrations recommended by the 
manufacturer and incubated at 4°C in the dark for 30–40 
min. After staining, cells were washed with phosphate-
buffered saline containing 0.1% sodium azide (FACS 
buffer 2), fixed using 4% PFA and cytometric analysis was 
performed in a FACS LSR II (BD Biosciences) cytometer 
in accordance with the manufacturer’s protocols. In brief, 
unstained cells, CD44, CD24 and double-stained control 
cells were used to mark the four quadrants in a dot-
plot for unstained, CD44+, CD24+ and double-positive 
populations. The change in percentage of CD44+/CD24− 
cells (top left quadrant) was measured in control and 
samples.
Statistical analysis
Statistical analysis was used to support the main 
conclusions in this study. Unless otherwise specified, all 
experiments were performed at least three times. The 
sample size for each experiment is provided in the relevant 
figure legends and represents biological replicates/
independent experiments performed on different days. 
Unless otherwise stated, statistical significance in Western 
blotting and in-ovo growth was evaluated with Student´s 
t-test. Statistical significance in the rest of the experiments 
was evaluated using an analysis of variance (ANOVA) 
complemented by Tukey’s honest significance difference 
test (Tukey’s HSD) performed in GraphPad PRISM 
software. Statistical significance levels are annotated as ns, 
not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
****, p < 0.0001.
Author contributions
DA conceived the project. IMDP and BL 
performed most of the experiments. MS performed FACS 
experiments. YZ performed the EM experiments. LY 
and TA performed the bioinformatics analysis of gene 
expression. CO-L performed in ovo growth experiments 
and provided technical assistance. IMDP, BL and DA 
designed experiments, interpreted results, and wrote the 
manuscript.
ACKNOWLEDGMENTS
The authors are grateful for support from the Cell 
Imaging Core and from the Finnish Functional Genomic 
Centre (Turku Centre for Biotechnology, Turku, Finland). 
We thank Dr. Jukka Westermarck for providing siRNA 
targeting H-ras. We thank Dr. Gunter Fischer (MPF for 
Enzymology of Protein Folding, Halle/Saale, Germany) 
for the kind gift of DM-CHX.
CONFLICTS OF INTEREST
The authors declare no potential conflicts of interest.
FINANCIAL SUPPORT
This work was supported by the Academy of 
Finland grants (#292611) to TA and (#252381, 256440, 
281497), the Sigrid Juselius Foundation, and the Jane and 
Aatos Erkko Foundation grants to DA. The funders had no 
role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript.
REFERENCES
1. Kreso A, Dick JE. Evolution of the Cancer Stem Cell 
Model. Cell Stem Cell. 2014; 14:275-91.
2. Clevers H. The cancer stem cell: premises, promises and 
challenges. Nat Med. 2011; 17:313-9.
3. Dontu G. In vitro propagation and transcriptional profiling 
of human mammary stem/progenitor cells. Genes Dev. 
2003; 17:1253-70.
4. Wander SA, Hennessy BT, Slingerland JM. Next-generation 
mTOR inhibitors in clinical oncology: how pathway 
complexity informs therapeutic strategy. J Clin Invest. 
2011; 121:1231-41.
5. Ilagan E, Manning BD. Emerging Role of mTOR in the 
Response to Cancer Therapeutics. Trends in Cancer. 2016; 
2:241-51.
6. Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, 
Cosin-Roger J, Lang S, Scharl M, Rogler G. Mutant HRAS 
as novel target for MEK and mTOR inhibitors. Oncotarget. 
2015; 6:42183-96. doi: 10.18632/oncotarget.5619.
7. Laplante M, Sabatini DM. mTOR signaling in growth 
control and disease. Cell. 2012; 149:274-93.
8. Spiegel J, Cromm PM, Zimmermann G, Grossmann TN, 
Waldmann H. Small-molecule modulation of ras signaling. 
Nat Chem Biol. 2014; 10:1-10.
9. Sabatini DM. mTOR and cancer: insights into a complex 
relationship. Nat Rev Cancer. 2006; 6:729-34.
10. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings 
BC, Ahmed M, Fehrenbacher N, Linder ME, Philips 
MR. FKBP12 binds to acylated H-ras and promotes 
depalmitoylation. Mol Cell. 2011; 41:173-85.
11. Prior IA, Lewis PD, Mattos C. A comprehensive survey of 
Ras mutations in cancer. Cancer Res. 2012; 72:2457-67.
12. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, 
Balmain A, McCormick F. K-Ras Promotes Tumorigenicity 
through Suppression of Non-canonical Wnt Signaling. Cell. 
2015; 163:1237-51.
13. Najumudeen AK, Jaiswal A, Lectez B, Oetken-Lindholm C, 
Guzman C, Siljamäki E, Posada IM, Lacey E, Aittokallio T, 
Abankwa D. Cancer stem cell drugs target K-ras signaling 
in a stemness context. Oncogene. 2016; 35:5248-5262.
Oncotarget44565www.impactjournals.com/oncotarget
14. Quinlan MP, Quatela SE, Philips MR, Settleman J. 
Activated Kras, but not Hras or Nras, may initiate tumors of 
endodermal origin via stem cell expansion. Mol Cell Biol. 
2008; 28:2659-74.
15. Abankwa D, Hanzal-Bayer M, Ariotti N, Plowman SJ, 
Gorfe AA, Parton RG, McCammon JA, Hancock JF. A 
novel switch region regulates H-ras membrane orientation 
and signal output. EMBO J. 2008; 27:727-35.
16. Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras 
membrane orientation and nanodomain localization 
generate isoform diversity. Proc Natl Acad Sci USA. 2010; 
107:1130-5.
17. Tian T, Harding A, Inder K, Plowman S, Parton RG, 
Hancock JF. Plasma membrane nanoswitches generate 
high-fidelity Ras signal transduction. Nat Cell Biol. 2007; 
9:905-14.
18. Guzmán C, Šolman M, Ligabue A, Blaževitš O, Andrade 
DM, Reymond L, Eggeling C, Abankwa D. The efficacy 
of Raf kinase recruitment to the GTPase H-ras depends on 
H-ras membrane conformer-specific nanoclustering. J Biol 
Chem. 2014; 289:9519-33.
19. Blaževitš O, Mideksa YG, Šolman M, Ligabue A, Ariotti N, 
Nakhaeizadeh H, Fansa EK, Papageorgiou AC, Wittinghofer 
A, Ahmadian MR, Abankwa D. Galectin-1 dimers can 
scaffold Raf-effectors to increase H-ras nanoclustering. Sci 
Rep. 2016; 6:24165.
20. Lefranc F, Mathieu V, Kiss R. Galectin-1 as an oncotarget 
in gliomas and melanomas. Oncotarget. 2011; 2:892-3. 
doi: 10.18632/oncotarget.408.
21. Wang F, Lv P, Gu Y, Li L, Ge X, Guo G. Galectin-1 
knockdown improves drug sensitivity of breast cancer by 
reducing P-glycoprotein expression through inhibiting the 
Raf-1/AP-1 signaling pathway. Oncotarget. 2017; 8:25097-
25106. doi: 10.18632/oncotarget.15341.
22. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, 
Serova M, Neuzillet C, Albert S, Raymond E, Faivre S. 
Unraveling galectin-1 as a novel therapeutic target for 
cancer. Cancer Treat Rev. 2014; 40:307-19.
23. Najumudeen AK, Posada IMD, Lectez B, Zhou Y, Landor 
SKJ, Fallarero A, Vuorela P, Hancock J, Abankwa D. 
Phenotypic Screening Identifies Protein Synthesis Inhibitors 
as H-Ras-Nanocluster-Increasing Tumor Growth Inducers. 
Biochemistry. 2015; 54:7212-21.
24. Zhou Y, Liang H, Rodkey T, Ariotti N, Parton RG, Hancock 
JF. Signal integration by lipid-mediated spatial cross 
talk between Ras nanoclusters. Mol Cell Biol. 2014; 34: 
862-876.
25. Posada IMD, Serulla M, Zhou Y, Oetken-Lindholm 
C, Abankwa D, Lectez B. ASPP2 Is a Novel Pan-Ras 
Nanocluster Scaffold. PLoS One. 2016; 11:e0159677.
26. Siljamäki E, Abankwa D. SPRED1 interferes with K-ras 
but not H-ras membrane anchorage and signaling. Mol Cell 
Biol. 2016; 36:2612-25.
27. Bar-Sagi D, Feramisco JR. Microinjection of the ras 
oncogene protein into PC12 cells induces morphological 
differentiation. Cell. 1985; 42:841-8.
28. Rotblat B, Niv H, André S, Kaltner H, Gabius HJ, Kloog 
Y. Galectin-1(L11A) predicted from a computed galectin-1 
farnesyl-binding pocket selectively inhibits Ras-GTP. 
Cancer Res. 2004; 64:3112-8.
29. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena 
L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma 
SC, Papa A, Nardella C, Cantley LC, et al. Inhibition of 
mTORC1 leads to MAPK pathway activation through a 
PI3K-dependent feedback loop in human cancer. J Clin 
Invest. 2008; 118:3065-74.
30. Lokman NA, Elder ASF, Ricciardelli C, Oehler MK. Chick 
chorioallantoic membrane (CAM) assay as an in vivo 
model to study the effect of newly identified molecules on 
ovarian cancer invasion and metastasis. Int J Mol Sci. 2012; 
13:9959-70.
31. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen 
E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, 
Robertson F, Xu W, Lacerda L, et al. Characterizing cancer 
cells with cancer stem cell-like features in 293T human 
embryonic kidney cells. Mol Cancer. 2010; 9:180.
32. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. 
Galectin-1 augments Ras activation and diverts Ras signals 
to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol 
Chem. 2002; 277:37169-75.
33. Edlich F, Weiwad M, Wildemann D, Jarczowski F, Kilka 
S, Moutty MC, Jahreis G, Lücke C, Schmidt W, Striggow 
F, Fischer G. The specific FKBP38 inhibitor N-(N',N'-
dimethylcarboxamidomethyl)cycloheximide has potent 
neuroprotective and neurotrophic properties in brain 
ischemia. J Biol Chem. 2006; 281:14961-70.
34. März AM, Fabian AK, Kozany C, Bracher A, Hausch F. 
Large FK506-binding proteins shape the pharmacology of 
rapamycin. Mol Cell Biol. 2013; 33:1357-67.
35. Pospelova TV, Bykova TV, Zubova SG, Katolikova NV, 
Yartzeva NM, Pospelov VA. Rapamycin induces pluripotent 
genes associated with avoidance of replicative senescence.
Cell Cycle. 2013; 12:3841-51.
36. Michael JV, Wurtzel JGT, Goldfinger LE. Inhibition of 
Galectin-1 Sensitizes HRAS-driven Tumor Growth to 
Rapamycin Treatment. Anticancer Res. 2016; 36:5053-61.
37. Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, 
Hoye TR, Mayo KH. Structure-Based Optimization of 
Angiostatic Agent 6DBF7, an Allosteric Antagonist of 
Galectin-1. J Pharmacol Exp Ther. 2013; 344:589-599.
38. Pool SE, Bison S, Koelewijn SJ, van der Graaf LM, Melis 
M, Krenning EP, de Jong M. mTOR Inhibitor RAD001 
Promotes Metastasis in a Rat Model of Pancreatic 
Neuroendocrine Cancer. Cancer Res. 2013; 73:12-8.
39. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. 
Galectin-1 binds oncogenic H-Ras to mediate Ras 
Oncotarget44566www.impactjournals.com/oncotarget
membrane anchorage and cell transformation. Oncogene. 
2001; 20:7486-93.
40. Plowman SJ, Muncke C, Parton RG, Hancock JF. H-ras, 
K-ras, and inner plasma membrane raft proteins operate 
in nanoclusters with differential dependence on the actin 
cytoskeleton. Proc Natl Acad Sci USA. 2005; 102:15500-5.
41. Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni 
V, Haapaniemi P, Corthais G, Aittokallio T, Westermarck 
J, Imanishi SY. Label-free quantitative phosphoproteomics 
with novel pairwise abundance normalization reveals 
synergistic RAS and CIP2A signaling. Sci Rep. 2015; 
5:13099.
42. Prior IA, Muncke C, Parton RG, Hancock JF. Direct 
visualization of Ras proteins in spatially distinct cell surface 
microdomains. J Cell Biol. 2003; 160:165-70.
43. Prior IA, Parton RG, Hancock JF. Observing cell surface 
signaling domains using electron microscopy. Sci STKE. 
2003; 2003:PL9.
44. Plowman SJ, Ariotti N, Goodall A, Parton RG, Hancock 
JF. Electrostatic interactions positively regulate K-Ras 
nanocluster formation and function. Mol Cell Biol. 2008; 
28:4377-85.
45. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a 
Bioconductor package for differential expression analysis 
of digital gene expression data. Bioinformatics. 2009; 
26:139-40.
46. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, 
Smyth GK. limma powers differential expression analyses 
for RNA-sequencing and microarray studies. Nucleic Acids 
Res. 2015; 43:e47.
